INTI Stock Chart & Stats
$0.09
>-$0.01(-7.73%)
At close: 4:00 PM EDT
$0.09
>-$0.01(-7.73%)
Day’s Range― - ―
52-Week Range$0.04 - $0.12
Previous CloseN/A
Volume21.23K
Average Volume (3M)12.58K
Market Cap
$13.29M
Enterprise Value$13.44M
Total Cash (Recent Filing)$1.29M
Total Debt (Recent Filing)$58.36K
Price to Earnings (P/E)―
Beta0.61
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding172,573,550
10 Day Avg. Volume14,764
30 Day Avg. Volume12,583
Financial Highlights & Ratios
PEG Ratio1.52
Price to Book (P/B)-6.01
Price to Sales (P/S)0.00
P/FCF Ratio-2.40
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.93
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Inhibitor Therapeutics News
INTI FAQ
What was Inhibitor Therapeutics Inc.’s price range in the past 12 months?
Inhibitor Therapeutics Inc. lowest stock price was $0.04 and its highest was $0.12 in the past 12 months.
What is Inhibitor Therapeutics Inc.’s market cap?
Inhibitor Therapeutics Inc.’s market cap is $13.29M.
When is Inhibitor Therapeutics Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Inhibitor Therapeutics Inc.’s earnings last quarter?
Inhibitor Therapeutics Inc. released its earnings results on May 01, 2018. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.003.
Is Inhibitor Therapeutics Inc. overvalued?
According to Wall Street analysts Inhibitor Therapeutics Inc.’s price is currently Overvalued.
Does Inhibitor Therapeutics Inc. pay dividends?
Inhibitor Therapeutics Inc. does not currently pay dividends.
What is Inhibitor Therapeutics Inc.’s EPS estimate?
Inhibitor Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inhibitor Therapeutics Inc. have?
Inhibitor Therapeutics Inc. has 172,573,550 shares outstanding.
What happened to Inhibitor Therapeutics Inc.’s price movement after its last earnings report?
Inhibitor Therapeutics Inc. reported an EPS of -$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Inhibitor Therapeutics Inc.?
Currently, no hedge funds are holding shares in INTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Inhibitor Therapeutics Inc.
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Technical Analysis
Kiora Pharmaceuticals
―
Genprex
―
Cyclerion Therapeutics
―
Artelo Biosciences
―
Dogwood Therapeutics
―